[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100487794":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":45,"responsibleParty":63,"collaborators":66,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":50,"enrollmentInfo":81,"targetDuration":50,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":48,"whyStopped":50,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Oslo University Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Flecainide and Metoprolol","EXPERIMENTAL","Participants will receive flecainide 50 mg twice daily (BID), with a dosage target of 100 mg BID. The maximum daily dose of flecainide will not exceed 300 mg. The first dose of flecainide will be initiated in-hospital with a 12-lead electrocardiogram (ECG) taken after 3 hours. If the ECG is considered normal after flecainide treatment, the participant will continue with 50 mg BID from the next day. Participants will receive a dosage of Metoprolol taking into consideration prior beta-blocker use and concomitant medications. The maximum daily dose of metoprolol will not exceed 200 mg. Within the run-in period, the dosage of both Flecainide and Metoprolol will be increased to the maximum tolerable dose.\n\nThe Study Team can change the immediate-release formulation of Flecainide to controlled release at the same daily dose of flecainide. Whether metoprolol sustained release will be dosed once daily (QD) or BID, will be up to the investigator and patient preference.",[13,14],"Drug: Flecainide","Drug: Metoprolol",{"label":16,"type":17,"description":18,"interventionNames":19},"Metoprolol Alone","ACTIVE_COMPARATOR","Participants will receive a dosage of Metoprolol taking into consideration prior beta-blocker use and concomitant medications. Within the run-in period, the dosage will be increased to the maximum tolerable dose. Whether metoprolol sustained release will be dosed QD or BID, will be up to the investigator and patient preference. The maximum daily dose of metoprolol will not exceed 200 mg.",[14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Flecainide","Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.",[9],[27],"C01B C04",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Metoprolol","Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.",[9,16],[33],"C07A B02",[35],{"name":36,"affiliation":37,"role":38},"Eivind W Aabel, MD PhD","Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway","PRINCIPAL_INVESTIGATOR",[40],{"name":36,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","41243148","+47","eivind.westrum.aabel@gmail.com",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Oslo University Hospital Rikshospitalet","RECRUITING","Oslo",null,"0372","Norway","NO",{"type":55,"coordinates":56},"Point",[57,58],10.74609,59.91273,{"lat":58,"lon":57},[61],{"name":62,"role":41,"phone":50,"phoneExt":50,"email":50},"Eivind W Aabel, MD",{"type":38,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":50,"oldOrganization":50},"Eivind Westrum Aabel","Principal Investigator",[67,69],{"name":68,"class":6},"The Research Council of Norway",{"name":70,"class":6},"University of Oslo","100487794","phase-3-effect-and-safety-of-flecainide-and-metoprolol-versus-metoprolol-alone-to-suppress-ventricular-arrhythmias-in-arrhythmic-mitral-valve-prolapse-100487794",false,"NCT05631730","Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse","An Investigator-Initiated Prospective Randomized Open-Label Blinded-Endpoint Crossover Trial Comparing the Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse","FLECAPRO","Inclusion Criteria:\n\n* Participants must be 18 years of age or older at the time of signing the informed consent.\n* Participants must have mitral valve prolapse evident by echocardiography or cardiac magnetic resonance imaging, defined as more than or equal to 2 mm atrial displacement of any part of the mitral leaflets.\n* Participants must have ventricular arrhythmias, defined as at least one of the following (i) premature ventricular complex burden ≥3% per 24 hours by Holter monitoring, (ii) premature ventricular complex burden ≥1% per 24 hours if multifocal or occurring in bi-\u002Ftrigemini and\u002For couplets by Holter monitoring, (iii) sustained or non-sustained ventricular tachycardia, (iv) aborted cardiac arrest.\n* Participants must have a clinical indication for antiarrhythmic treatment due to ventricular arrhythmias.\n* Participants must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).\n* Participants (only women of childbearing) must accede to mandatory use of a contraceptive method for the duration of the trial and until 3 days after discontinuation of study medication.\n\nExclusion Criteria:\n\n* Strict contraindications to flecainide or metoprolol use\n* Heart failure (signs or symptoms, elevated N-terminal proBNP)\n* Abnormal liver or kidney function (Aspartate aminotransferase (AST)\u002FAlanine aminotransferase (ALT) three times upper normal, estimated glomerular filtration (eGRF) \\\u003C60)\n* Prior myocardial infarction or ischemic heart disease\n* Ion channelopathy, including Brugada syndrome and long QT syndrome\n* Genetic cardiomyopathy (hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, dilated cardiomyopathy, including genotype positive phenotype negative individuals)\n* Atrial flutter or permanent atrial fibrillation\n* Sinus node dysfunction\n* Ongoing electrolyte disorders\n* More than moderate valvular disease according to international guidelines\n* Pre-excitation\n* Any degree of AV-block, except due to enhanced vagal tone (e.g. Wenckebach-block at night in young athletes or 1st-degree AV block that disappears during exercise)\n* Bundle branch block (QRS duration \\>120 ms) or intraventricular conduction defect with QRS \\>120 ms.\n* Prior flecainide therapy.\n* Concomitant use of the following medications (i) CYP2D6 inhibitors\u002Finducers, (ii) class I, III or IV antiarrhythmic drugs, (iii) clozapine, quinidine, cimetidine, bupropion, or (iii) monoamineoxidase (MAO) inhibitors\n* Pregnancy\n* Not willing to use a mandatory contraceptive method for the duration of the trial.","ALL","18 Years",{"count":82,"type":83},50,"ESTIMATED","INTERVENTIONAL",[86],"PHASE3","FLECAPRO is a randomized controlled crossover trial assessing the effect and safety of adding flecainide to standard beta-blocker therapy to reduce the burden of ventricular arrhythmias in patients with arrhythmic mitral valve prolapse. The primary endpoint of will be assessed using an implantable loop recorder with blinded endpoint adjudication.",[89,90],"Mitral Valve Prolapse","Ventricular Arrhythmias and Cardiac Arrest",[92,93,94],"arrhythmic mitral valve prolapse","mitral annular disjunction","ventricular arrhythmia","2025-07-29",{"date":97,"type":98},"2025-07-30","ACTUAL",{"date":100,"type":98},"2023-01-04",{"date":102,"type":83},"2026-06",{"name":5,"class":6},1]